Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Recruiting

Phase 2

Darolutamide vs. Standard TherapyNeoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Sponsor:

Vandana Abramson

Code:

NCT07016399

Conditions

Anatomic Stage II Breast Cancer AJCC v8

Anatomic Stage IIIA Breast Cancer AJCC v8

Triple-Negative Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Breast Biopsy Procedure

Carboplatin

Cyclophosphamide

Darolutamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-09. This information was provided to ClinicalTrials.gov by Vandana Abramson on 2025-10-30.